This study is to evaluate the effectiveness and safety of Ultimaster Tansei stent and/or Ultimaster Nagomi stent in the "real-world" daily practice.
Patients ≥ 19 years old
Patients receiving Ultimaster™ Tansei™ stent and/or Ultimaster Nagomi™ stents.
The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
Patients with a mixture of other drug-eluting stents (DESs)
Terminal illness with life-expectancy ≤1 year.
Patients with cardiogenic shock
Duk-Woo Park, MD
Lead sponsor
Asan Medical Center
Sponsor institution
CardioVascular Research Foundation, Korea
Collaborator